Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vericel Corp develops autologous stem/progenitor cell products for the repair/regeneration of tissues based on Tissue Repair Cell (TRC) adult stem cell technology. The Company"s products contain bone marrow stem and progenitor cells that are produced from cells originating from the patient.
Website: vcel.com


  • Good financial results growth rate 27.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.3%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.4% (LTM)
  • Share price is 16.4% higher than minimum and 43.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (74.3x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $2.6 mln (-0.146% of cap.)

Key Financials (Download financials)

Ticker: VCEL
Share price, USD:  (-0.4%)34.74
year average price 37.40  


year start price 43.52 2025-05-20

max close price 45.70 2025-06-10

min close price 29.84 2025-09-25

current price 34.74 2026-05-19
Common stocks: 50 340 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.4%
EV / LTM EBITDA: 74.3x
EV / EBITDA annualized: 16.5x
Last revenue growth (y/y):  +24.0%
Last growth of EBITDA (y/y):  +30.0%
Historical revenue growth:  +18.7%
Historical growth of EBITDA:  0.0%
EV / Sales: 6.2x
Margin (EBITDA LTM / Revenue): 8.3%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 749
Net Debt ($m): -41
EV (Enterprise Value): 1 708
EBITDA LTM (млн $): 23
EV / LTM EBITDA: 74.3x
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-14seekingalpha.com

Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-06seekingalpha.com

Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript

2025-09-11zacks.com

Is the Options Market Predicting a Spike in Vericel Stock?

2025-08-28globenewswire.com

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

2025-07-31zacks.com

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

2025-03-05seekingalpha.com

Vericel: Scalable Growth With Strong Margins

2025-02-27seekingalpha.com

Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript

2025-02-27globenewswire.com

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

2025-02-13globenewswire.com

Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025

2025-02-03zacks.com

Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359
fillingDate 2025-11-06 2025-07-31 2024-11-07 2024-08-01 2024-05-08 2023-11-08 2023-08-02 2023-05-10 2022-11-09
acceptedDate 2025-11-06 08:47:30 2025-07-31 08:50:37 2025-02-27 08:57:34 2024-11-07 08:48:55 2024-08-01 09:05:00 2024-05-08 08:59:38 2024-02-29 09:04:36 2023-11-08 09:11:58 2023-08-02 08:47:56 2023-05-10 08:49:30 2023-02-23 09:03:02 2022-11-09 08:52:27 2022-02-24 09:03:00 2021-02-24 16:48:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 68M 63M 237M 58M 53M 51M 198M 46M 46M 41M 164M 39M 156M 124M
costOfRevenue 18M 17M 65M 16M 16M 16M 62M 15M 16M 14M 55M 13M 50M 40M
grossProfit 50M 47M 172M 42M 37M 35M 136M 31M 30M 27M 110M 25M 106M 84M
grossProfitRatio 0.735 0.737 0.719 0.695 0.689 0.672 0.652 0.647 0.655
researchAndDevelopmentExpenses 6M 7M 25M 6M 7M 6M 21M 6M 5M 5M 20M 5M 16M 13M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 40M 42M 143M 38M 35M 34M 121M 30M 31M 29M 107M 27M 98M 69M
otherExpenses 0 0 0 0 -8000 -7000 0 -1000 -5000 -12 000 0 0 0 0
operatingExpenses 46M 49M 168M 44M 43M 41M 142M 36M 36M 35M 127M 32M 114M 82M
costAndExpenses 64M 65M 233M 60M 59M 57M 204M 51M 52M 49M 181M 45M 164M 122M
interestIncome 2M 2M 6M 2M 2M 2M 5M 1M 1M 839 000 1M 342 000 224 000 691 000
interestExpense 158 000 157 000 614 000 154 000 153 000 153 000 600 000 150 000 149 000 145 000 366 000 105 000 4000 6000
depreciationAndAmortization 3M 3M 6M 1M 1M 1M 5M 1M 1M 827 000 4M 1M 3M 2M
ebitda 8M 2M 17M 579 000 -3M -4M 3M -3M -5M -7M -12M -5M -5M 5M
ebitdaratio 0.121 0.038 0.01 -0.089 -0.08 -0.058 -0.106 -0.179 -0.141
operatingIncome 3M -2M 5M -2M -6M -5M -6M -5M -6M -8M -17M -7M -8M 2M
operatingIncomeRatio 0.051 -0.032 -0.043 -0.115 -0.107 -0.111 -0.13 -0.199 -0.176
totalOtherIncomeExpensesNet 2M 1M 6M 2M 1M 2M 4M -1000 -5000 682 000 1M 232 000 272 000 672 000
incomeBeforeTax 5M -553 000 11M -901 000 -5M -4M -2M -4M -5M -7M -16M -7M -8M 3M
incomeBeforeTaxRatio 0.075 -0.009 -0.016 -0.089 -0.075 -0.087 -0.109 -0.183 -0.17
incomeTaxExpense 0 0 148 000 0 0 1M 814 000 -286 000 -946 000 -1M 721 000 21 000 -111 000 180 000
netIncome 5M -553 000 10M -901 000 -5M -4M -3M -4M -5M -6M -17M -7M -7M 3M
netIncomeRatio 0.075 -0.009 -0.016 -0.089 -0.075 -0.08 -0.109 -0.154 -0.171
eps 0.1 -0.011 0.21 -0.018 -0.096 -0.08 -0.067 -0.077 -0.11 -0.13 -0.35 -0.14 -0.16 0.063
epsdiluted 0.098 -0.011 -0.018 -0.096 -0.08 -0.077 -0.11 -0.13 -0.14
weightedAverageShsOut 50M 50M 49M 49M 49M 48M 48M 48M 48M 47M 47M 47M 46M 45M
weightedAverageShsOutDil 52M 50M 52M 49M 49M 48M 48M 48M 48M 47M 47M 47M 46M 47M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 6M 4M 975 000 220 000 685 000
ebit 11M -2M -16M -8M 3M
nonOperatingIncomeExcludingInterest -7M -5M -1M -276 000 -678 000
netIncomeFromContinuingOperations 10M -3M -17M -7M 3M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 10M -3M -17M -7M 3M
epsDiluted 0.2 -0.067 -0.35 -0.16 0.061

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359
fillingDate 2025-11-06 2025-07-31 2024-11-07 2024-08-01 2024-05-08 2023-11-08 2023-08-02 2023-05-10 2022-11-09
acceptedDate 2025-11-06 08:47:30 2025-07-31 08:50:37 2025-02-27 08:57:34 2024-11-07 08:48:55 2024-08-01 09:05:00 2024-05-08 08:59:38 2024-02-29 09:04:36 2023-11-08 09:11:58 2023-08-02 08:47:56 2023-05-10 08:49:30 2023-02-23 09:03:02 2022-11-09 08:52:27 2022-02-24 09:03:00 2021-02-24 16:48:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 100M 81M 75M 54M 76M 71M 69M 60M 43M 62M 51M 65M 68M 34M
shortTermInvestments 35M 36M 42M 48M 52M 48M 40M 45M 55M 57M 68M 46M 35M 42M
cashAndShortTermInvestments 135M 117M 116M 102M 128M 118M 110M 105M 98M 119M 120M 111M 103M 76M
netReceivables 60M 64M 61M 48M 48M 50M 58M 40M 38M 38M 47M 34M 37M 35M
inventory 18M 17M 17M 16M 15M 14M 13M 13M 14M 15M 16M 17M 13M 9M
otherCurrentAssets 8M 7M 18M 25M 32M 8M 25M 5M 5M 5M 5M 4M 4M 4M
totalCurrentAssets 222M 205M 213M 191M 197M 190M 206M 186M 183M 178M 187M 166M 158M 124M
propertyPlantEquipmentNet 175M 177M 173M 160M 146M 130M 115M 104M 98M 59M 57M 59M 59M 58M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 6M 6M 6M 6M 7M 7M 7M 7M 7M 7M 8M 0 0 0
goodwillAndIntangibleAssets 6M 6M 6M 6M 7M 7M 7M 7M 7M 7M 8M 0 0 0
longTermInvestments 50M 47M 40M 33M 26M 29M 25M 20M 21M 20M 20M 22M 26M 24M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 395 000 447 000 556 000 610 000 664 000 717 000 771 000 1M 1M 1M 1M 1M 528 000 211 000
totalNonCurrentAssets 231M 231M 220M 200M 179M 167M 148M 132M 128M 88M 86M 82M 85M 82M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 453M 436M 433M 390M 377M 357M 354M 318M 311M 265M 273M 248M 244M 206M
accountPayables 15M 13M 24M 21M 25M 19M 22M 15M 14M 11M 17M 8M 9M 7M
shortTermDebt 28M 28M 0 6M 12M 6M 0 7M 7M 4M 0 5M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 14M 0 0 0 0 0
otherCurrentLiabilities 3M 769 000 14M 14M 7M 11M 13M 14M 21 000 13M 10M 14M 10M 9M
totalCurrentLiabilities 46M 41M 50M 41M 44M 36M 46M 36M 36M 29M 37M 27M 26M 22M
longTermDebt 86M 86M 0 91M 90M 86M 0 78M 76M 42M 0 43M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 2M 876 000 243 000 198 000 154 000 100 000 0 28 000 0 0 30M 0 0
totalNonCurrentLiabilities 86M 88M 90M 92M 90M 86M 82M 78M 76M 42M 43M 43M 47M 49M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 100M 100M 99M 97M 96M 86M 88M 85M 83M 47M 48M 48M 50M 53M
totalLiabilities 131M 129M 141M 133M 134M 123M 128M 114M 112M 71M 81M 70M 73M 71M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 721M 711M 685M 670M 655M 641M 629M 621M 612M 602M 593M 585M 554M 510M
retainedEarnings -400M -405M -393M -413M -412M -407M -403M -416M -413M -407M -400M -406M -383M -376M
accumulatedOtherComprehensiveIncomeLoss 258 000 183 000 4000 359 000 -273 000 -245 000 -100 000 -463 000 -621 000 -636 000 -978 000 -1M -154 000 14 000
othertotalStockholdersEquity 0 0 0 0 0 0 0 0 0
totalStockholdersEquity 322M 307M 292M 257M 243M 234M 226M 204M 199M 194M 192M 178M 170M 134M
totalEquity 322M 307M 292M 257M 243M 234M 226M 204M 199M 194M 192M 178M 170M 134M
totalLiabilitiesAndStockholdersEquity 453M 436M 390M 377M 357M 318M 311M 265M 248M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 453M 436M 433M 390M 377M 357M 354M 318M 311M 265M 273M 248M 244M 206M
totalInvestments 85M 84M 82M 81M 78M 77M 66M 65M 76M 77M 88M 67M 61M 66M
totalDebt 98M 100M 99M 97M 96M 92M 88M 85M 83M 47M 48M 48M 50M 53M
netDebt -2M 19M 24M 44M 20M 22M 19M 25M 40M -15M -3M -17M -18M 20M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 61M 58M 47M 37M 35M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 24M 22M 17M 9M 7M
otherPayables 0 0 0 0 0
accruedExpenses 3M 4M 6M 4M 2M
capitalLeaseObligationsCurrent 9M 6M 4M 3M 4M
capitalLeaseObligationsNonCurrent 90M 82M 43M 47M 49M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL VCEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359 887 359
fillingDate 2025-11-06 2025-07-31 2024-11-07 2024-08-01 2024-05-08 2023-11-08 2023-08-02 2023-05-10 2022-11-09
acceptedDate 2025-11-06 08:47:30 2025-07-31 08:50:37 2025-02-27 08:57:34 2024-11-07 08:48:55 2024-08-01 09:05:00 2024-05-08 08:59:38 2024-02-29 09:04:36 2023-11-08 09:11:58 2023-08-02 08:47:56 2023-05-10 08:49:30 2023-02-23 09:03:02 2022-11-09 08:52:27 2022-02-24 09:03:00 2021-02-24 16:48:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 5M -553 000 10M -901 000 -5M -4M -3M -4M -5M -7M -17M -7M -7M 3M
depreciationAndAmortization 3M 3M 6M 784 000 1M 1M 5M 1M 1M 1M 4M 1M 3M 2M
deferredIncomeTax 0 0 0 0 0 0 0 -286 000 -214 000 0 721 000 0 949 000 411 000
stockBasedCompensation 9M 10M 36M 9M 10M 10M 32M 8M 9M 9M 37M 9M 34M 14M
changeInWorkingCapital 4M -6M -450 000 -1M 11M -2M -4M 156 000 4M 5M -11M -449 000 -6M -6M
accountsReceivables 4M -11M -3M -483 000 2M 8M -12M -1M 40 000 8M -9M -632 000 -3M -2M
inventory -1M 275 000 -4M -869 000 -1M -470 000 3M 1M 1M 616 000 -3M -800 000 -4M -3M
accountsPayables 3M 8000 -287 000 -1M 5M -5M 3M -596 000 1M -274 000 1M -1M 1M 33 000
otherWorkingCapital -1M 6M 7M 2M 6M -5M 2M 900 000 1M -4M -939 000 2M -687 000 -2M
otherNonCashItems 1M 1M 6M 2M 8M 11M 6M 2M 1M 888 000 4M 1M 4M 4M
netCashProvidedByOperatingActivities 22M 8M 58M 10M 19M 7M 35M 7M 10M 8M 18M 4M 29M 18M
investmentsInPropertyPlantAndEquipment -3M 14M 0 31M -17M -14M 0 -7M -4M -9M -8M -1M -8M -3M
acquisitionsNet 0 0 0 0 0 0 0 7M 4M 9M 8M 0 8M 3M
purchasesOfInvestments -15M -16M -68M -17M -13M -23M -55M -8M -19M -10M -70M -9M -60M -63M
salesMaturitiesOfInvestments 14M 15M 53M 15M 12M 11M 80M 19M 21M 22M 41M 10M 64M 49M
otherInvestingActivites 0 -22M -50M -17M -14M -7M -4M -9M 0
netCashUsedForInvestingActivites -3M -9M -21M -18M -25M 5M -2M 3M -811 000
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 1M 2M 6M 4M 7M 1M 1M 2M 829 000
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -316 000 -147 000 -271 000 -138 000 -5M -107 000 -78 000 -2M -1M
netCashUsedProvidedByFinancingActivities 1M 2M 6M 4M 2M 1M 1M 107 000 -312 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 -5M -4M 0 0 0 0 0
netChangeInCash 20M 827 000 -2M -6M 5M -16M 36M 13M 9M 11M -17M 3M 35M 7M
cashAtEndOfPeriod 100M 81M 85M 70M 76M 71M 87M 84M 71M 62M 51M 65M 69M 34M
cashAtBeginningOfPeriod 81M 80M 87M 76M 71M 87M 51M 71M 62M 51M 69M 62M 34M 27M
operatingCashFlow 22M 8M 58M 10M 19M 7M 35M 7M 10M 8M 18M 4M 29M 18M
capitalExpenditure -3M 14M -64M 31M -17M -14M -28M -7M -4M -9M -8M -1M -8M -3M
freeCashFlow 19M 22M -6M 41M 2M -7M 8M 600 000 6M -1M 10M 3M 21M 15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-29 2023-02-23 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -64M -28M -8M -8M -3M
netCashProvidedByInvestingActivities -79M -3M -36M -4M -17M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 25M 6M 4M 11M 7M
netCommonStockIssuance 25M 6M 4M 11M 7M
commonStockIssuance 25M 6M 4M 11M 7M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -5M -2M -3M -2M -191 000
netCashProvidedByFinancingActivities 19M 4M 1M 9M 6M
incomeTaxesPaid 628 000 1M 0 379 000 147 000
interestPaid 399 000 383 000 0 4000 6000

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-07 11:45 ET
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
2026-04-23 12:30 ET
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
2026-04-02 ET
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
2026-03-04 ET
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
2026-03-03 ET
Vericel to Present at Multiple Upcoming Investor Conferences
2026-02-26 ET
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
2026-02-12 13:30 ET
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
2026-01-13 ET
Vericel Announces Preliminary 2025 Financial Results and Business Updates
2026-01-06 ET
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
2025-11-14 ET
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
2025-11-06 ET
Vericel Reports Third Quarter 2025 Financial Results
2025-10-23 ET
Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025
2025-08-28 ET
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
2025-07-31 ET
Vericel Reports Second Quarter 2025 Financial Results
2025-07-17 ET
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
2025-06-10 ET
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
2025-05-08 ET
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
2025-05-07 ET
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
2025-04-24 ET
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
2025-03-04 ET
Vericel to Present at Multiple Upcoming Investor Conferences
2025-02-27 ET
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
2025-02-13 ET
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
2025-01-14 ET
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
2025-01-08 ET
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
2024-11-07 12:55 ET
Vericel Reports Third Quarter 2024 Financial Results
2024-10-24 12:30 ET
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
2024-08-29 13:17 ET
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
2024-08-26 11:45 ET
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
2024-08-15 20:05 ET
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
2024-08-07 12:30 ET
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
2024-08-01 11:55 ET
Vericel Reports Second Quarter 2024 Financial Results
2024-07-22 12:30 ET
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
2024-07-18 12:30 ET
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
2024-06-11 12:30 ET
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
2024-05-22 12:30 ET
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
2024-05-08 11:55 ET
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
2024-04-24 12:30 ET
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
2024-02-29 12:55 ET
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
2024-02-27 13:30 ET
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
2024-02-15 13:30 ET
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
2024-02-05 13:30 ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
2024-01-09 12:55 ET
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
2024-01-03 13:30 ET
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
2023-11-08 12:55 ET
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
2023-11-07 13:30 ET
Vericel to Present at the Stephens Annual Investment Conference
2023-10-25 12:30 ET
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
2023-09-28 12:30 ET
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
2023-09-20 20:30 ET
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
2023-09-06 12:30 ET
Vericel to Present at the Morgan Stanley Global Healthcare Conference
2023-08-02 11:55 ET
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
2023-07-20 12:30 ET
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
2023-05-10 11:55 ET
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
2023-05-02 13:00 ET
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor
2023-04-26 12:30 ET
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
2023-02-28 13:30 ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
2023-02-23 12:55 ET
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
2023-02-09 13:00 ET
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
2023-01-10 12:55 ET
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
2023-01-04 13:34 ET
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
2022-12-29 18:46 ET
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
2022-12-29 18:45 ET
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
2022-11-10 14:00 ET
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
2022-11-09 12:55 ET
Vericel Reports Third Quarter 2022 Financial Results
2022-10-26 12:30 ET
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
2022-09-22 12:30 ET
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
2022-09-06 12:30 ET
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
2022-08-03 11:55 ET
Vericel Reports Second Quarter 2022 Financial Results
2022-08-03 11:30 ET
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
2022-07-21 20:05 ET
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
2022-07-20 12:30 ET
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
2022-05-04 11:55 ET
Vericel Reports First Quarter 2022 Financial Results
2022-04-20 12:30 ET
Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022
2022-03-15 12:30 ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
2022-03-01 13:30 ET
Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
2022-02-24 21:45 ET
Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
2022-02-24 12:55 ET
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
2022-02-10 14:00 ET
Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
2022-02-02 21:05 ET
Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth
2022-01-04 13:30 ET
Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
2021-11-11 13:30 ET
Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021
2021-11-09 12:40 ET
Vericel Reports Third Quarter 2021 Financial Results
2021-10-21 12:30 ET
Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
2021-09-08 12:30 ET
Vericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021
2021-09-07 12:30 ET
Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
2021-08-04 12:00 ET
Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
2021-07-21 12:30 ET
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
2021-07-07 12:30 ET
Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021
2021-06-29 12:45 ET
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
2021-06-29 12:45 ET
Vericel Provides Regulatory Update for NexoBrid
2021-06-09 13:00 ET
Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
2021-06-02 12:30 ET
Vericel Announces Appointment of Lisa Wright to Board of Directors
2021-05-13 12:30 ET
Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
2021-05-05 11:00 ET
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
2021-04-21 12:30 ET
Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
2021-04-09 13:24 ET
Vericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021
2021-03-10 13:30 ET
Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
2021-03-02 13:30 ET
Vericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
2021-02-24 13:00 ET
Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance
2021-02-22 13:30 ET
Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
2021-02-16 13:30 ET
Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
2021-02-12 13:30 ET
Vericel Announces Termination of Shareholder Rights Agreement
2021-02-10 13:00 ET
Vericel to Report Fourth-Quarter 2020 Financial Results on February 24, 2021
2021-01-25 13:30 ET
Vericel Announces Appointment of Joe Mara as Chief Financial Officer
2021-01-11 12:15 ET
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates
2021-01-08 13:30 ET
Vericel to Present at the 23rd Annual Needham Growth Conference on Friday, January 15, 2021
2021-01-07 13:30 ET
Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
2020-12-18 13:30 ET
Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
2020-11-05 13:00 ET
Vericel Reports Record Third Quarter Revenues and Net Income
2020-11-02 13:30 ET
Vericel to Present at Upcoming Investor Conferences
2020-10-22 12:30 ET
Vericel to Report Third-Quarter 2020 Financial Results on November 5, 2020
2020-10-14 12:00 ET
Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million
2020-10-09 12:30 ET
Vericel To Host Virtual Analyst and Investor Day on October 16, 2020
2020-09-16 11:30 ET
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
2020-09-16 11:30 ET
Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
2020-09-09 12:30 ET
Vericel to Present at Multiple Upcoming Investor Conferences
2020-09-04 12:30 ET
Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020
2020-08-25 11:00 ET
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
2020-08-25 11:00 ET
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
2020-08-05 12:00 ET
Vericel Reports Second Quarter 2020 Financial Results
2020-07-22 12:30 ET
Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020
2020-07-09 12:30 ET
Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates
2020-06-30 11:00 ET
Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
2020-05-13 12:30 ET
Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020
2020-05-05 12:00 ET
Vericel Reports First Quarter 2020 Financial Results
2020-04-22 12:30 ET
Vericel to Report First-Quarter 2020 Financial Results on May 5, 2020
2020-04-10 13:00 ET
Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders
2020-04-08 12:30 ET
Vericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020
2020-04-02 13:00 ET
Vericel Provides Business and Financial Updates
2020-02-25 13:00 ET
Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance
2020-02-24 15:04 ET
Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
2020-02-19 13:00 ET
Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020
2020-02-11 13:00 ET
Vericel to Report Fourth-Quarter 2019 Financial Results on February 25, 2020
2020-01-09 13:00 ET
Vericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020
2020-01-06 11:30 ET
BARDA Initiates the Procurement of NexoBrid for Emergency Response
2019-11-06 14:00 ET
Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel
2019-11-05 13:00 ET
Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow
2019-10-22 12:30 ET
Vericel to Report Third-Quarter 2019 Financial Results on November 5, 2019
2019-10-02 11:30 ET
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
2019-09-27 12:00 ET
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
2019-09-18 12:00 ET
Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

SEC forms

Show financial reports only

SEC form 10
2026-05-07 12:54 ET
Vericel published news for 2026 q1
SEC form 8
2026-05-07 11:57 ET
Vericel published news for 2026 q1
SEC form 8
2026-05-07 11:57 ET
Vericel published news for 2026 q1
SEC form 8
2026-05-01 20:05 ET
Vericel published news for 2026 q1
SEC form 10
2026-02-26 09:00 ET
Vericel reported for 2025 q4
SEC form 8
2026-02-26 08:02 ET
Vericel published news for 2025 q4
SEC form 8
2026-02-26 08:02 ET
Vericel published news for 2025 q4
SEC form 10
2025-11-06 08:47 ET
Vericel reported for 2025 q3
SEC form 8
2025-11-06 08:03 ET
Vericel published news for 2025 q3
SEC form 8
2025-11-06 08:03 ET
Vericel published news for 2025 q3
SEC form 10
2025-07-31 12:50 ET
Vericel reported for 2025 q2
SEC form 8
2025-07-31 12:14 ET
Vericel published news for 2025 q2
SEC form 8
2025-07-31 12:14 ET
Vericel published news for 2025 q2
SEC form 10
2025-05-08 12:53 ET
Vericel reported for 2025 q1
SEC form 8
2025-05-08 12:04 ET
Vericel published news for 2025 q1
SEC form 8
2025-05-08 12:04 ET
Vericel published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Vericel published news for 2025 q1
SEC form 10
2025-02-27 08:57 ET
Vericel reported for 2024 q4
SEC form 8
2025-02-27 08:00 ET
Vericel published news for 2024 q4
SEC form 8
2025-02-27 08:00 ET
Vericel published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Vericel published news for 2024 q4
SEC form 8
2025-01-14 00:00 ET
Vericel published news for 2024 q4
SEC form 8
2025-01-14 00:00 ET
Vericel published news for 2024 q4
SEC form 8
2025-01-14 00:00 ET
Vericel published news for 2024 q4
SEC form 10
2024-11-07 08:48 ET
Vericel published news for 2024 q3
SEC form 8
2024-11-07 08:01 ET
Vericel published news for 2024 q3
SEC form 8
2024-11-07 08:01 ET
Vericel published news for 2024 q3
SEC form 10
2024-08-01 09:05 ET
Vericel reported for 2024 q2
SEC form 8
2024-08-01 08:04 ET
Vericel published news for 2024 q2
SEC form 8
2024-08-01 08:04 ET
Vericel published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Vericel published news for 2024 q2
SEC form 10
2024-05-08 08:59 ET
Vericel published news for 2024 q1
SEC form 8
2024-05-08 08:10 ET
Vericel published news for 2024 q1
SEC form 8
2024-05-08 08:10 ET
Vericel reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Vericel published news for 2024 q1
SEC form 10
2024-02-29 09:04 ET
Vericel published news for 2023 q4
SEC form 8
2024-02-29 08:04 ET
Vericel published news for 2023 q4
SEC form 8
2024-02-29 08:04 ET
Vericel reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Vericel published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Vericel published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Vericel published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Vericel published news for 2023 q4
SEC form 10
2023-11-08 09:11 ET
Vericel published news for 2023 q3
SEC form 8
2023-11-08 08:06 ET
Vericel reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Vericel published news for 2023 q3
SEC form 10
2023-08-02 08:47 ET
Vericel reported for 2023 q2
SEC form 6
2023-08-02 08:03 ET
Vericel published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Vericel published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Vericel published news for 2023 q2
SEC form 10
2023-05-10 00:00 ET
Vericel published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Vericel published news for 2023 q1
SEC form 10
2023-02-23 09:03 ET
Vericel reported for 2022 q4
SEC form 6
2023-02-23 08:02 ET
Vericel published news for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Vericel reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Vericel reported for 2022 q4
SEC form 6
2023-01-10 16:10 ET
Vericel published news for 2022 q4
SEC form 8
2023-01-10 00:00 ET
Vericel published news for 2022 q4
SEC form 6
2022-12-29 16:05 ET
Vericel published news for 2022 q3
SEC form 10
2022-11-09 08:52 ET
Vericel reported for 2022 q3
SEC form 6
2022-11-09 08:04 ET
Vericel published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Vericel published news for
SEC form 8
2022-11-09 00:00 ET
Vericel reported for 2022 q3
SEC form 10
2022-08-03 09:04 ET
Vericel reported for 2022 q2
SEC form 6
2022-08-03 08:16 ET
Vericel published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Vericel reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Vericel reported for 2022 q2
SEC form 6
2022-08-02 16:05 ET
Vericel published news for 2022 q2
SEC form 10
2022-05-04 08:51 ET
Vericel reported for 2022 q1
SEC form 6
2022-05-04 08:15 ET
Vericel published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Vericel reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Vericel reported for 2022 q1
SEC form 6
2022-04-29 16:37 ET
Vericel published news for 2022 q1
SEC form 6
2022-03-17 08:26 ET
Vericel published news for 2021 q4
SEC form 6
2022-02-24 17:17 ET
Vericel published news for 2021 q4
SEC form 10
2022-02-24 09:03 ET
Vericel published news for 2021 q4
SEC form 6
2022-02-24 08:15 ET
Vericel published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Vericel published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Vericel published news for 2021 q4
SEC form 6
2022-02-02 16:06 ET
Vericel published news for 2021 q4
SEC form 6
2022-01-12 07:25 ET
Vericel published news for 2021 q4
SEC form 8
2022-01-12 00:00 ET
Vericel published news for 2021 q4
SEC form 10
2021-11-09 09:14 ET
Vericel published news for 2021 q3
SEC form 6
2021-11-09 08:23 ET
Vericel published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Vericel published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Vericel published news for 2021 q3
SEC form 6
2021-08-27 17:11 ET
Vericel published news for 2021 q2
SEC form 10
2021-08-04 16:08 ET
Vericel published news for 2021 q2
SEC form 6
2021-08-04 08:07 ET
Vericel published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Vericel published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Vericel published news for 2021 q2
SEC form 6
2021-06-29 16:30 ET
Vericel published news for 2021 q1
SEC form 6
2021-06-21 16:15 ET
Vericel published news for 2021 q1
SEC form 6
2021-06-02 08:40 ET
Vericel published news for 2021 q1
SEC form 10
2021-05-05 08:06 ET
Vericel published news for 2021 q1
SEC form 6
2021-05-05 07:14 ET
Vericel published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Vericel published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Vericel published news for 2021 q1
SEC form 6
2021-04-29 16:52 ET
Vericel published news for 2021 q1
SEC form 6
2021-03-19 08:00 ET
Vericel published news for 2020 q4
SEC form 10
2021-02-24 16:48 ET
Vericel published news for 2020 q4
SEC form 6
2021-02-24 08:42 ET
Vericel published news for 2020 q4
SEC form 6
2021-02-12 08:56 ET
Vericel published news for 2020 q4
SEC form 6
2021-01-25 08:35 ET
Vericel published news for 2020 q4
SEC form 6
2021-01-11 07:30 ET
Vericel published news for 2020 q4
SEC form 10
2020-11-05 15:11 ET
Vericel published news for 2020 q3
SEC form 6
2020-11-05 09:27 ET
Vericel published news for 2020 q3
SEC form 6
2020-10-14 08:00 ET
Vericel published news for 2020 q3